Mark J. Foley, CEO at Revance Therapeutics, Inc. (RVNC), bought 30,000 shares at $6.98 ($209K) on 2024-03-06, disclosed to the SEC on 2024-03-08.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| RVNC | SELL | 2023-08-04 | $1.2M | — | Filing → |
| RVNC | SELL | 2023-07-05 | $1.3M | — | Filing → |
| RVNC | SELL | 2023-06-13 | $1.9M | — | Filing → |